BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 07/11/23

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Bell2Bell Podcast . The podcast is part of...

LOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sus...

Although the world is through the worst of the coronavirus pandemic and most of the population has moved on from the disease, a small subset of the population still deals with COVID-19 to this day. These are people who are still suffering from symptoms such as insomnia, lightheadedness, extreme...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize...

On average, asthma affects close to 26 million people, or 1 in every 13 people in the United States with nearly 21 million adults aged 18 years and older suffering from the respiratory condition. Doctors advise most asthma patients to follow steps such as religiously taking medication, implemen...

MoonLake (NASDAQ: MLTX) , a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, has announced positive top-line results from its global phase 2 MIRA trial. The trial (“M1095-HS-201”) evaluated the efficacy and safety of the Nanobo...

MoonLake (NASDAQ: MLTX) , a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, has announced positive top-line results from its global phase 2 MIRA trial. The trial (“M1095-HS-201”) evaluated the efficacy and safety of the Nanobo...

Most people with multiple sclerosis (MS) are women ( 74% ), while men comprise only 24% of MS patients. Women are three times more likely to develop multiple sclerosis, and the National Multiple Sclerosis Society states that more women are developing the condition as time passes.  Although w...

BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis Part of an ongoing broad-based collaboration targeting therapies addressing diseases such ...

Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs BiondVax enjoys an exclusive option for an exclusiv...